Security key
21077P108
Context Therapeutics Inc. - Common Stock, $0.001 par value (CNTX)
CUSIP: 21077P108
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 269,057
- Total 13F value
- $148,707
- Share change
- +261,479
- SEC-reported price per share
- $0.55
- Number of holders
- 6
- Value change
- +$144,833
- Number of buys
- 3
- Shares outstanding
- 92,424,242
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
6
Top holders
6
CNTX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Context Therapeutics Inc. SEC filings
Context Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 21077P108
Recent filing periods:
Ownership snapshot
Top reported holders of CNTX - Context Therapeutics Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MPM BioImpact LLC
Disclosed value leader
MPM BioImpact LLC
Comparable rows
15/15
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 12%
13D/G row: MPM BioImpact LLC
Showing 1-6 of 15 holder rows.
Quick read
MPM BioImpact LLC leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MPM BioImpact LLC's linked filing trail.
Comparable ownership
Top 5
MPM BioImpact LLC
12%
Avidity Partners Management LP
8.7%
Deep Track Capital, LP
8.3%
Soleus Capital Master Fund, L.P.
7.6%
BlackRock, Inc.
6.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MPM BioImpact LLC |
13F
13D/G
Company
|
12%
from 13D/G
|
$27,980,004
10,679,391 shares
|
— | 31 Mar 2026 |
| Avidity Partners Management LP |
13D/G
13F
Company
|
8.7%
|
$21,753,357
8,302,808 shares
|
-$2,352,163 | 31 Mar 2026 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
8.3%
from 13D/G
|
$19,438,710
7,419,355 shares
|
— | 31 Mar 2026 |
| Soleus Capital Master Fund, L.P. |
13D/G
|
7.6%
|
$18,243,429
6,963,141 shares
|
+$5,729,267 | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
6.7%
|
$3,401,108
6,169,250 shares
|
$0 | 30 Jun 2026 |
| Blue Owl Capital Holdings LP |
13D/G
13F
Company
|
5.5%
|
$13,333,219
5,089,015 shares
|
-$3,324,552 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
6
Shares
269,057
Rows available
6
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q4 2025 Across Filers
Q4 2025 holders
42
Q2 2026 holders
6
Holder diff
-36
| Investor | Q4 2025 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend